㰀栀琀洀氀㸀
㰀氀椀渀欀 爀攀氀㴀∀猀琀礀氀攀猀栀攀攀琀∀ 琀礀瀀攀㴀∀琀攀砀琀⼀挀猀猀∀ 栀爀攀昀㴀∀猀琀礀氀攀⸀挀猀猀∀⼀㸀
㰀戀漀搀礀㸀
Centre de Référence des Rhumatismes Inflammatoires et Maladies Autoimmunes Systémiques Rares de l’Enfant (RAISE) / 2017
56
Time
to
treatment
as
an
important factor for the response
to
methotrexate
in
juvenile
idiopathic arthritis. Arthritis Care Res 2009; 61:46–51
Traitements
Beukelman T, Patkar NM, Saag
KG,
American
Rheumatology
College
of
recommendations
for
arthritis:
initiation
and
safety
monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care
Res
(Hoboken).
Apr;63(4):465–82.
2011
Davies R, Gaynor D, Hyrich KL,
Pain
therapy
juvenile
individual
arthritis
subtypes:
Semin
Arthritis
2017
Foell
D,
Wulffraat
Frosch
M,
Gerss
J,
et
al.
Methotrexate withdrawal at 6 vs 12
arthritis
in
remission:
JAMA.
2010 Apr 7;303(13):1266–73.
Ringold
Colbert
RA, DeWitt EM, Lee T, Onel K, et
Rheumatology
treatment
plans for new-onset polyarticular
juvenile
idiopathic
(Hoboken).
2014 Jul;66(7):1063–72.
Traitements
des
formes
polyarticulaires graves
Tynjälä
P,
Vähäsalo
P,
Tarkiainen M, Kröger L, Aalto K, Malin M, et al. Aggressive combination
very
juvenile
early
polyarticular
idiopathic
randomised
open-label
clinical trial. Ann Rheum Dis. 2011 Sep;70(9):1605–12.
Wallace
Spalding
Giannini
Hashkes
Trial
of
therapy juvenile Arthritis
idiopathic
Rheum.
Jun;64(6):2012–21.
Infiltrations intra-articulaires
Ravelli
van
versus
corticosteroids
intra-articular
plus
methotrexate
multicentre,
Atteinte oculaire
Biester
al.
Adalimumab
therapy
Ophthalmol.
2007 Mar;91(3):319–24.